Upstream Bio (UPB) Common Equity (2023 - 2026)

Upstream Bio's Common Equity history runs 4 years deep, the most recent figure standing at $304.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 31.78% year-over-year to $304.0 million; the TTM figure through Mar 2026 stood at $304.0 million (down 31.78% YoY), while the FY2025 annual figure was $339.8 million, down 27.69% from the prior year.
• Common Equity was $304.0 million for Q1 2026 at Upstream Bio, down from $339.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $469.9 million in Q4 2024 to a low of -$160.3 million in Q3 2024.
• Historically, Common Equity has averaged $151.9 million across 4 years, with a median of $304.0 million in 2026.
• Biggest YoY gain for Common Equity was 481.6% in 2024; the steepest drop was 42.87% in 2024.
• A 4-year view of Common Equity shows it stood at -$123.1 million in 2023, then jumped by 481.6% to $469.9 million in 2024, then dropped by 27.69% to $339.8 million in 2025, then dropped by 10.53% to $304.0 million in 2026.
• The last three Common Equity figures came in at $304.0 million (Q1 2026), $339.8 million (Q4 2025), and $378.6 million (Q3 2025), per Business Quant data.